Literature DB >> 31564624

Optimization of the transition process of youth with liver disease in adulthood: A position paper from FILFOIE, the French network for paediatric and adult rare liver diseases.

Teresa Maria Antonini1, Muriel Girard2, Dalila Habes3, Odile Goria4, Dominique Debray2.   

Abstract

Transition describes a progressive and highly coordinated process encompassing the transfer of a young patient from paediatric care to the adult-care system. Transfer of medical care for an adolescent to adult services is a complex and challenging task requiring close collaboration of both the paediatric and adult-care providers. It must take into account the medical, psychosocial and educational needs of the young adult. The Transition Working Group of the French Network for Rare Liver Diseases (FILFOIE) proposes recommendations and tools designed to optimise the transition process of adolescents and young adults with chronic liver disease from child-based to adult-based healthcare services, focusing on three key time points: preparation before the transfer, the transfer process to the adult service, and finally reception and follow-up within the adult-care service.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Adolescent; Liver disease; Liver transplantation; Transition; Young adults

Mesh:

Year:  2019        PMID: 31564624     DOI: 10.1016/j.clinre.2019.07.018

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  1 in total

1.  Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey.

Authors:  Delphine Genevaz; Armelle Arnoux; Catherine Marcel; Anaïs Brassier; Samia Pichard; François Feillet; François Labarthe; Brigitte Chabrol; Marc Berger; Anne-Sophie Lapointe; Yvann Frigout; Bénédicte Héron; Gilles Chatellier; Nadia Belmatoug
Journal:  Orphanet J Rare Dis       Date:  2022-02-21       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.